Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Portola Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Portola Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Portola Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Portola Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Portola Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Portola Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Portola Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Portola Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Portola Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Portola Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Portola Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Portola Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Portola Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Portola Pharmaceuticals, Inc. Snapshot 5 Portola Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Portola Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Portola Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Portola Pharmaceuticals, Inc. - Pipeline Products Glance 11 Portola Pharmaceuticals, Inc. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Portola Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Portola Pharmaceuticals, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Portola Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 15 Unknown Products/Combination Treatment Modalities 15 Portola Pharmaceuticals, Inc. - Drug Profiles 16 betrixaban 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 PRT-4445 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 PRT-2070 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PRT-2607 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PRT-060318 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PRT-061103 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Portola Pharmaceuticals, Inc. - Pipeline Analysis 23 Portola Pharmaceuticals, Inc. - Pipeline Products by Target 23 Portola Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 24 Portola Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 25 Portola Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 26 Portola Pharmaceuticals, Inc. - Recent Pipeline Updates 27 Portola Pharmaceuticals, Inc. - Dormant Projects 34 Portola Pharmaceuticals, Inc. - Discontinued Pipeline Products 35 Discontinued Pipeline Product Profiles 35 betrixaban 35 elinogrel potassium 35 PRT-2607 35 Portola Pharmaceuticals, Inc. - Locations And Subsidiaries 36 Head Office 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Portola Pharmaceuticals, Inc., Key Information 5 Portola Pharmaceuticals, Inc., Key Facts 5 Portola Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Portola Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Portola Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Portola Pharmaceuticals, Inc. - Phase III, 2014 11 Portola Pharmaceuticals, Inc. - Phase II, 2014 12 Portola Pharmaceuticals, Inc. - Phase I, 2014 13 Portola Pharmaceuticals, Inc. - Preclinical, 2014 14 Portola Pharmaceuticals, Inc. - Unknown, 2014 15 Portola Pharmaceuticals, Inc. - Pipeline by Target, 2014 23 Portola Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 24 Portola Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 25 Portola Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 26 Portola Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 27 Portola Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 34 Portola Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.